132 related articles for article (PubMed ID: 30711390)
1. Discovery of novel pan-genotypic HCV NS5A inhibitors containing a novel tetracyclic core.
Yu W; Hu B; Zhong B; Hao J; Lei Z; Agrawal S; Rokosz L; Liu R; Chen S; Asante-Appiah E; Kozlowski JA
Bioorg Med Chem Lett; 2019 Mar; 29(5):700-706. PubMed ID: 30711390
[TBL] [Abstract][Full Text] [Related]
2. Discovery of Chromane Containing Hepatitis C Virus (HCV) NS5A Inhibitors with Improved Potency against Resistance-Associated Variants.
Yu W; Tong L; Hu B; Zhong B; Hao J; Ji T; Zan S; Coburn CA; Selyutin O; Chen L; Rokosz L; Agrawal S; Liu R; Curry S; McMonagle P; Ingravallo P; Asante-Appiah E; Chen S; Kozlowski JA
J Med Chem; 2016 Nov; 59(22):10228-10243. PubMed ID: 27792320
[TBL] [Abstract][Full Text] [Related]
3. Discovery of fused tricyclic core containing HCV NS5A inhibitors with pan-genotype activity.
Yu W; Coburn CA; Yang DY; Meinke PT; Wong M; Rosenblum SB; Chen KX; Njoroge GF; Chen L; Dwyer MP; Jiang Y; Nair AG; Selyutin O; Tong L; Zeng Q; Zhong B; Ji T; Hu B; Agrawal S; Xia E; Zhai Y; Liu R; Kong R; Ingravallo P; Asante-Appiah E; Nomeir A; Fells J; Kozlowski JA
Bioorg Med Chem Lett; 2016 Jul; 26(13):3158-3162. PubMed ID: 27180013
[TBL] [Abstract][Full Text] [Related]
4. MK-8325: A silyl proline-containing NS5A inhibitor with pan-genotype activity for treatment of HCV.
Nair AG; Zeng Q; Selyutin O; Rosenblum SB; Jiang Y; Yang DY; Keertikar K; Zhou G; Dwyer M; Kim SH; Shankar B; Yu W; Tong L; Chen L; Mazzola R; Caldwell J; Tang H; Agrawal S; Liu R; Kong R; Ingravallo P; Xia E; Zhai Y; Nomeir A; Asante-Appiah E; Kozlowski JA
Bioorg Med Chem Lett; 2018 Jun; 28(10):1954-1957. PubMed ID: 29653894
[TBL] [Abstract][Full Text] [Related]
5. Discovery of silyl proline containing HCV NS5A inhibitors with pan-genotype activity: SAR development.
Nair AG; Zeng Q; Selyutin O; Rosenblum SB; Jiang Y; Yang DY; Keertikar K; Zhou G; Dwyer MP; Kim SH; Shankar B; Yu W; Tong L; Chen L; Mazzola R; Caldwell J; Tang H; Allard ML; Buckle RN; Gauuan PJ; Holst CL; Martin GS; Naicker KP; Vellekoop S; Agrawal S; Liu R; Kong R; Ingravallo P; Xia E; Zhai Y; Nomeir A; Kozlowski JA
Bioorg Med Chem Lett; 2016 Mar; 26(5):1475-9. PubMed ID: 26850003
[TBL] [Abstract][Full Text] [Related]
6. Aryl or heteroaryl substituted aminal derivatives of HCV NS5A inhibitor MK-8742.
Yu W; Coburn CA; Nair AG; Wong M; Rosenblum SB; Zhou G; Dwyer MP; Tong L; Hu B; Zhong B; Hao J; Ji T; Zan S; Kim SH; Zeng Q; Selyutin O; Chen L; Masse F; Agrawal S; Liu R; Xia E; Zhai Y; Curry S; McMonagle P; Ingravallo P; Asante-Appiah E; Lin M; Kozlowski JA
Bioorg Med Chem Lett; 2016 Aug; 26(15):3414-20. PubMed ID: 27394665
[TBL] [Abstract][Full Text] [Related]
7. Discovery of MK-8742: an HCV NS5A inhibitor with broad genotype activity.
Coburn CA; Meinke PT; Chang W; Fandozzi CM; Graham DJ; Hu B; Huang Q; Kargman S; Kozlowski J; Liu R; McCauley JA; Nomeir AA; Soll RM; Vacca JP; Wang D; Wu H; Zhong B; Olsen DB; Ludmerer SW
ChemMedChem; 2013 Dec; 8(12):1930-40. PubMed ID: 24127258
[TBL] [Abstract][Full Text] [Related]
8. Discovery of Ruzasvir (MK-8408): A Potent, Pan-Genotype HCV NS5A Inhibitor with Optimized Activity against Common Resistance-Associated Polymorphisms.
Tong L; Yu W; Chen L; Selyutin O; Dwyer MP; Nair AG; Mazzola R; Kim JH; Sha D; Yin J; Ruck RT; Davies IW; Hu B; Zhong B; Hao J; Ji T; Zan S; Liu R; Agrawal S; Xia E; Curry S; McMonagle P; Bystol K; Lahser F; Carr D; Rokosz L; Ingravallo P; Chen S; Feng KI; Cartwright M; Asante-Appiah E; Kozlowski JA
J Med Chem; 2017 Jan; 60(1):290-306. PubMed ID: 27808515
[TBL] [Abstract][Full Text] [Related]
9. Discovery of ABT-267, a pan-genotypic inhibitor of HCV NS5A.
DeGoey DA; Randolph JT; Liu D; Pratt J; Hutchins C; Donner P; Krueger AC; Matulenko M; Patel S; Motter CE; Nelson L; Keddy R; Tufano M; Caspi DD; Krishnan P; Mistry N; Koev G; Reisch TJ; Mondal R; Pilot-Matias T; Gao Y; Beno DW; Maring CJ; Molla A; Dumas E; Campbell A; Williams L; Collins C; Wagner R; Kati WM
J Med Chem; 2014 Mar; 57(5):2047-57. PubMed ID: 24400777
[TBL] [Abstract][Full Text] [Related]
10. Discovery and Characterization of Potent Pan-Genotypic HCV NS5A Inhibitors Containing Novel Tricyclic Central Core Leading to Clinical Candidate.
Ramdas V; Talwar R; Banerjee M; Joshi AA; Das AK; Walke DS; Borhade P; Dhayagude U; Loriya R; Gote G; Bommakanti A; Sivaram A; Agarwal G; Goswami A; Nigade P; Mehta M; Patil V; Modi D; Kumar H; Mallurwar S; Dash A; Modi F; Kuldharan S; Srivastava P; Singh M; Narasimham L; Gundu J; Sharma S; Kamboj RK; Palle VP
J Med Chem; 2019 Dec; 62(23):10563-10582. PubMed ID: 31710479
[TBL] [Abstract][Full Text] [Related]
11. Discovery of ravidasvir (PPI-668) as a potent pan-genotypic HCV NS5A inhibitor.
Zhong M; Peng E; Huang N; Huang Q; Huq A; Lau M; Colonno R; Li L
Bioorg Med Chem Lett; 2016 Sep; 26(18):4508-4512. PubMed ID: 27506559
[TBL] [Abstract][Full Text] [Related]
12. Discovery of fluorobenzimidazole HCV NS5A inhibitors.
Randolph JT; Flentge CA; Donner P; Rockway TW; Patel SV; Nelson L; Hutchinson DK; Mondal R; Mistry N; Reisch T; Dekhtyar T; Krishnan P; Pilot-Matias T; Stolarik DF; Beno DWA; Wagner R; Maring C; Kati WM
Bioorg Med Chem Lett; 2016 Nov; 26(22):5462-5467. PubMed ID: 27780635
[TBL] [Abstract][Full Text] [Related]
13. Substituted tetracyclic indole core derivatives of HCV NS5A inhibitor MK-8742.
Yu W; Zhou G; Coburn CA; Zeng Q; Tong L; Dwyer MP; Hu B; Zhong B; Hao J; Ji T; Zan S; Chen L; Mazzola R; Kim JH; Sha D; Selyutin O; Rosenblum SB; Lavey B; Nair AG; Heon Kim S; Keertikar KM; Rokosz L; Agrawal S; Liu R; Xia E; Zhai Y; Curry S; McMonagle P; Ingravallo P; Asante-Appiah E; Chen S; Kozlowski JA
Bioorg Med Chem Lett; 2016 Oct; 26(19):4851-4856. PubMed ID: 27568086
[TBL] [Abstract][Full Text] [Related]
14. Discovery of a Silicon-Containing Pan-Genotype Hepatitis C Virus NS5A Inhibitor.
Liu B; Gai K; Qin H; Wang J; Liu X; Cao Y; Lu Q; Lu D; Chen D; Shen H; Song W; Mei J; Wang X; Xu H; Zhang Y
J Med Chem; 2020 May; 63(10):5312-5323. PubMed ID: 32293179
[TBL] [Abstract][Full Text] [Related]
15. Matched and mixed cap derivatives in the tetracyclic indole class of HCV NS5A inhibitors.
Dwyer MP; Keertikar KM; Chen L; Tong L; Selyutin O; Nair AG; Yu W; Zhou G; Lavey BJ; Yang DY; Wong M; Kim SH; Coburn CA; Rosenblum SB; Zeng Q; Jiang Y; Shankar BB; Rizvi R; Nomeir AA; Liu R; Agrawal S; Xia E; Kong R; Zhai Y; Ingravallo P; Asante-Appiah E; Kozlowski JA
Bioorg Med Chem Lett; 2016 Aug; 26(16):4106-11. PubMed ID: 27423481
[TBL] [Abstract][Full Text] [Related]
16. Discovery of MK-6169, a Potent Pan-Genotype Hepatitis C Virus NS5A Inhibitor with Optimized Activity against Common Resistance-Associated Substitutions.
Yu W; Tong L; Selyutin O; Chen L; Hu B; Zhong B; Hao J; Ji T; Zan S; Yin J; Ruck RT; Curry S; McMonagle P; Agrawal S; Rokosz L; Carr D; Ingravallo P; Bystol K; Lahser F; Liu R; Chen S; Feng KI; Cartwright M; Asante-Appiah E; Kozlowski JA
J Med Chem; 2018 May; 61(9):3984-4003. PubMed ID: 29681153
[TBL] [Abstract][Full Text] [Related]
17. Alkyl substituted aminal derivatives of HCV NS5A inhibitor MK-8742.
Yu W; Coburn CA; Nair AG; Wong M; Tong L; Dwyer MP; Hu B; Zhong B; Hao J; Yang DY; Selyutin O; Jiang Y; Rosenblum SB; Kim SH; Lavey BJ; Zhou G; Rizvi R; Shankar BB; Zeng Q; Chen L; Agrawal S; Carr D; Rokosz L; Liu R; Curry S; McMonagle P; Ingravallo P; Lahser F; Asante-Appiah E; Nomeir A; Kozlowski JA
Bioorg Med Chem Lett; 2016 Aug; 26(15):3800-5. PubMed ID: 27282742
[TBL] [Abstract][Full Text] [Related]
18.
Ng TI; Krishnan P; Pilot-Matias T; Kati W; Schnell G; Beyer J; Reisch T; Lu L; Dekhtyar T; Irvin M; Tripathi R; Maring C; Randolph JT; Wagner R; Collins C
Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28193664
[TBL] [Abstract][Full Text] [Related]
19. Discovery of velpatasvir (GS-5816): A potent pan-genotypic HCV NS5A inhibitor in the single-tablet regimens Vosevi
Link JO; Taylor JG; Trejo-Martin A; Kato D; Katana AA; Krygowski ES; Yang ZY; Zipfel S; Cottell JJ; Bacon EM; Tran CV; Yang CY; Wang Y; Wang KW; Zhao G; Cheng G; Tian Y; Gong R; Lee YJ; Yu M; Gorman E; Mogalian E; Perry JK
Bioorg Med Chem Lett; 2019 Aug; 29(16):2415-2427. PubMed ID: 31230974
[TBL] [Abstract][Full Text] [Related]
20. Alternative core development around the tetracyclic indole class of HCV NS5A inhibitors.
Tong L; Yu W; Coburn CA; Meinke PT; Nair AG; Dwyer MP; Chen L; Selyutin O; Rosenblum SB; Jiang Y; Fells J; Hu B; Zhong B; Soll RM; Liu R; Agrawal S; Xia E; Zhai Y; Kong R; Ingravallo P; Nomeir A; Asante-Appiah E; Kozlowski JA
Bioorg Med Chem Lett; 2016 Oct; 26(20):5132-5137. PubMed ID: 27634194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
